title: Adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a randomized controlled study.
abstract: OBJECTIVE
  To evaluate the effect of metformin in polycystic ovary syndrome (PCOS). As follow-up on a previous paper describing hormonal and metabolic factors, this paper focuses on correlations between adiponectin and anthropometric, hormonal, and metabolic factors in PCOS and the effect of metformin.
  
  
  METHODS
  Randomized, double-blind, placebo-controlled crossover study.
  
  
  METHODS
  District and university hospital.
  
  
  METHODS
  Fifty-two women with PCOS. Three groups were defined according to baseline adiponectin.
  
  
  METHODS
  Metformin or placebo for 6 months, followed by 3 months' washout before switching to opposite treatment. Blood tests and measurements were performed before and after treatment periods.
  
  
  METHODS
  Adiponectin, insulin, homeostasis model assessment (HOMA) index, and testosterone.
  
  
  RESULTS
  Waist-hip ratio (WHR), insulin, and HOMA index were significantly higher in the lower adiponectin group than in the upper and middle group, and high-density lipoprotein (HDL) cholesterol was higher in the upper than in the lower adiponectin group. Multiple regression analysis with adiponectin as the dependent variable and HOMA index, HDL cholesterol, testosterone, and WHR as independent variables showed an R(2) of 0.43 with β-coefficients of -0.12 for the HOMA index, 0.72 for HDL cholesterol, and -1.49 for WHR. Testosterone did not contribute to the prediction of adiponectin levels. Metformin had no effect on adiponectin in spite of significant decreases in weight, fasting glucose, and insulin resistance.
  
  
  CONCLUSIONS
  In PCOS, adiponectin levels are closely linked to insulin resistance, HDL cholesterol, and abdominal adiposity and unaffected by metformin.
authors.affiliation: Department of Obstetrics and Gynaecology, Aarhus University Hospital, Skejby, Denmark. ditte.trolle@dadlnet.dk
authors.forename: Birgitta
authors.initials: B
authors.lastname: Trolle
authors.forename: Finn Friis
authors.initials: FF
authors.lastname: Lauszus
authors.forename: Jan
authors.initials: J
authors.lastname: Frystyk
authors.forename: Allan
authors.initials: A
authors.lastname: Flyvbjerg
mesh_terms: D052242:Adiponectin / Q000032:analysis / Q000097:blood; D000293:Adolescent; D000328:Adult; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance / Q000502:physiology; D008687:Metformin / Q000494:pharmacology* / Q000627:therapeutic use*; D008875:Middle Aged; D010919:Placebos; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000188:drug therapy* / Q000378:metabolism; D013739:Testosterone / Q000097:blood; D055815:Young Adult
chemical_list: C499918:ADIPOQ protein, human; D052242:Adiponectin; D007004:Hypoglycemic Agents; D007328:Insulin; D010919:Placebos; D013739:Testosterone; D008687:Metformin